Diabetes Metab J.  2019 Jun;43(3):377-378. 10.4093/dmj.2018.0091.

Letter: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73)

• Kim KS

• KMID: 2454064
• DOI: http://doi.org/10.4093/dmj.2018.0091

Abstract

No abstract available.

MeSH Terms

Glucosides
Glycated Hemoglobin A
Sodium-Glucose Transporter 2 Inhibitors
Diabetes Mellitus, Type 2
Glomerular Filtration Rate
Glucosides
Glycated Hemoglobin A
Sodium-Glucose Transporter 2 Inhibitors

Reference

1. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes: 2019. Diabetes Care. 2019; 42:Suppl 1. S90–S102.

2. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41:2669–2701.

3. Lee JY, Cho Y, Lee M, Kim YJ, Lee YH, Lee BW, Cha BS, Kang ES. Predictors of the therapeutic efficacy and consideration of the best combination therapy of sodium-glucose co-transporter 2 inhibitors. Diabetes Metab J. 2019; 43:158–173.

4. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011; 13:928–938.

5. Bujac S, Del Parigi A, Sugg J, Grandy S, Liptrot T, Karpefors M, Chamberlain C, Boothman AM. Patient characteristics are not associated with clinically important differential response to dapagliflozin: a staged analysis of phase 3 data. Diabetes Ther. 2014; 5:471–482.

6. Scheen AJ. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. Expert Opin Drug Metab Toxicol. 2016; 12:1407–1417.

7. van Baar MJB, van Ruiten CC, Muskiet MHA, van Bloemendaal L, IJzerman RG, van Raalte DH. SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care. 2018; 41:1543–1556.